LekoskopLekoskop
EN All changes
Medicine recalls and shortages › New approvals › 6 Jul 2026
MHRA approval

Retifanlimab (ZYNYZ)

Published on 6 Jul 2026 · source: MHRA — Medicines and Healthcare products Regulatory Agency
Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that develops from Merkel cells, specialised neuroendocrine cells found in the top layer of the skin.  
MHRA announcement ↗ All events: Retifanlimab (ZYNYZ)

What this means

The MHRA has announced the approval of a medicine or a new indication in the UK. Approval does not mean the product is already available on the NHS: NICE appraisal and commissioning may follow.

Summary

Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that develops from Merkel cells, specialised neuroendocrine cells found in the top layer of the skin.  

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.